Study of Application of Transcutaneous Pulsed Electrical Stimulation Around Eye in Age-related Macular Degeneration
Primary Purpose
Early to Moderate Dry Age-Related Macular Degeneration
Status
Recruiting
Phase
Not Applicable
Locations
Korea, Republic of
Study Type
Interventional
Intervention
Transcutaneous Pulsed Electrical Stimulation (Device: Nu Eyne M02)
Sponsored by
About this trial
This is an interventional treatment trial for Early to Moderate Dry Age-Related Macular Degeneration focused on measuring Age-related macular degeneration, Macular degeneration, Early to Moderate Dry AMD
Eligibility Criteria
Inclusion Criteria:
- 50 years or older
Has a confirmed diagnosis of early to moderate AMD
According to Staging of age-related macular degeneration of Beckman Initiative for Macular Research Classification Committee
- early AMD: Medium drusen(>63 μm; ≤125 μm) and No AMD pigmentary abnormalities
- moderate AMD: Large drusen(>125 μm) and/or Any AMD pigmentary abnormalities
- Best Corrected Visual Acuity [BCVA] of 20/200 or better measured by Early Treatment Diabetic Retinopathy Study(ETDRS) Charts
- A person who voluntarily agreed to participate in this clinical trial
Exclusion Criteria:
- Subject who is observed to have a atrophy of 175 micrometers or more in diameter invading the fovea on fundus examination or fundus autofluorescent with more than one eye
- Subject who is observed to have exudative macular degeneration on fundus examination or optical coherence tomography(OCT) with more than one eye
- Has a history of intravitreal injection, laser treatment, etc.
- Has eye pathology other than early age-related macular degeneration that may affect the outcome of clinical trials.
- Has a history of vitrectomy due to macular disease or cataract surgery within 1 month
- Has a disease that is judged to be difficult to interpret an ophthalmic imaging examination due to ocular media opacity
- Has a history of uncontrollable systemic chronic disease(diabetes mellitus) or malignancy(Cases that have not recurred for more than 5 years after complete recovery are excluded)
- Autoimmune disease(Sjögren's syndrome, Rheumatoid arthritis, systemic lupus erythematosus, Graves' disease, etc.)
- Has a severe hearing impairment
- A person who is sensitive to orbit nerve stimulation and cannot be treated.
- Has a history of substance and/or alcohol abuse
- Has a confirmed diagnosis of psychiatric disease(depression, schizophrenia, bipolar disorder, dementia, etc)
- Those who participated in other clinical trials within 30 days of the screening visit
- Those who are judged to have "other reasons for prohibition of use" of our clinical trial medical device: heart-related problems. seizure. Patients transplanted metal or electronic device in head & neck including deep brain stimulation device. Patient suffering from unknown pain. Patients with implantable or wearable cardioverter defibrillator. Patients who are warned not to use out clinical trial device or is prohibited from using it. (Dental implants are accepted.)
- In the case of subjects judged by the researcher that it would be difficult to participate in clinical trials
Among female subjects who are likely to be pregnant, those who disagree to contraception in a medically permitted manner during this clinical trial period.
- Medically permitted contraception: condom, Oral contraception that lasted for at least 3 months, contraceptive injection, contraceptive implant, intrauterine device, etc.
Sites / Locations
- Korea University Ansan HospitalRecruiting
- Asan Medical CenterRecruiting
- Nune Eye Hospital
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Transcutaneous Pulsed Electrical Stimulation Treatment
Arm Description
Patients wear our clinical trial device 30mins once a day for 16weeks. Device: Nu eyne M02
Outcomes
Primary Outcome Measures
Number of Safety Events
Check the safety issues(AE, SAE, etc.).
Secondary Outcome Measures
Changes in contrast sensitivity
Check the change of contrast sensitivity in the baseline, 6, 16 weeks
Changes in score of VFQ-25(National Eye Institute)
Check the change of Changes in score of VFQ-25(National Eye Institute) in the baseline, 6, 16 weeks
Changes in best corrected visual acuity(Early Treatment Diabetic Retinopathy Study (ETDRS) Chart)
Check the change of best corrected visual acuity in the baseline, 6, 16 weeks
Changes in drusen area using optical coherence tomography(OCT)
Check the change of drusen area using optical coherence tomography(OCT) in the baseline, 6, 16 weeks
Changes in drusen volume using optical coherence tomography(OCT)
Check the change of drusen volume using optical coherence tomography(OCT) in the baseline, 6, 16 weeks
Progression to advanced Age-related Macular Degeneration (AMD) using fundus autofluorescence(FAF)
Check the Progression to advanced Age-related Macular Degeneration (AMD) using fundus autofluorescence(FAF) in the baseline, 6, 16 weeks
Progression to advanced Age-related Macular Degeneration (AMD) using fundus photography
Check the Progression to advanced Age-related Macular Degeneration (AMD) using fundus photography in the baseline, 6, 16 weeks
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT05259371
Brief Title
Study of Application of Transcutaneous Pulsed Electrical Stimulation Around Eye in Age-related Macular Degeneration
Official Title
A 16-Week, Multi-Center, Open-Label, Exploratory Study to Evaluate the Safety and Efficacy of the Application of Pulse Electrical Stimulation Around the Eye in Early to Moderate Dry Age-Related Macular Degeneration
Study Type
Interventional
2. Study Status
Record Verification Date
September 2023
Overall Recruitment Status
Recruiting
Study Start Date
October 5, 2022 (Actual)
Primary Completion Date
June 30, 2024 (Anticipated)
Study Completion Date
June 30, 2024 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Nu Eyne Co., Ltd.
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
This study aims to evaluate the safety and efficacy of applying pulse electrical stimulation around eyes of age-related macular patients.
Detailed Description
Duration of study period(per participant): Screening period(0-4weeks), Intervention period(16weeks) Patient needs to visit site at least 5 times(Screening, V2, V3, V4, V5). V2 can be done with screening visit. Visit 3, 4, 5 is 2weeks, 6weeks, and 16weeks after visit 2(Baseline).
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Early to Moderate Dry Age-Related Macular Degeneration
Keywords
Age-related macular degeneration, Macular degeneration, Early to Moderate Dry AMD
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Model Description
• Experimental: Transcutaneous Pulsed Electrical Stimulation Treatment Patients wear our clinical trial device 30mins once a day for 16weeks. Device: Nu eyne M02
Masking
None (Open Label)
Allocation
N/A
Enrollment
25 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Transcutaneous Pulsed Electrical Stimulation Treatment
Arm Type
Experimental
Arm Description
Patients wear our clinical trial device 30mins once a day for 16weeks. Device: Nu eyne M02
Intervention Type
Drug
Intervention Name(s)
Transcutaneous Pulsed Electrical Stimulation (Device: Nu Eyne M02)
Intervention Description
Pulse Electrical Stimulation Patients wear our clinical trial device 30mins once a day for 16weeks.
Primary Outcome Measure Information:
Title
Number of Safety Events
Description
Check the safety issues(AE, SAE, etc.).
Time Frame
baseline ~ 16 weeks
Secondary Outcome Measure Information:
Title
Changes in contrast sensitivity
Description
Check the change of contrast sensitivity in the baseline, 6, 16 weeks
Time Frame
baseline, 6, 16 weeks
Title
Changes in score of VFQ-25(National Eye Institute)
Description
Check the change of Changes in score of VFQ-25(National Eye Institute) in the baseline, 6, 16 weeks
Time Frame
baseline, 6, 16 weeks
Title
Changes in best corrected visual acuity(Early Treatment Diabetic Retinopathy Study (ETDRS) Chart)
Description
Check the change of best corrected visual acuity in the baseline, 6, 16 weeks
Time Frame
baseline, 6, 16 weeks
Title
Changes in drusen area using optical coherence tomography(OCT)
Description
Check the change of drusen area using optical coherence tomography(OCT) in the baseline, 6, 16 weeks
Time Frame
baseline, 6, 16 weeks
Title
Changes in drusen volume using optical coherence tomography(OCT)
Description
Check the change of drusen volume using optical coherence tomography(OCT) in the baseline, 6, 16 weeks
Time Frame
baseline, 6, 16 weeks
Title
Progression to advanced Age-related Macular Degeneration (AMD) using fundus autofluorescence(FAF)
Description
Check the Progression to advanced Age-related Macular Degeneration (AMD) using fundus autofluorescence(FAF) in the baseline, 6, 16 weeks
Time Frame
baseline, 6, 16 weeks
Title
Progression to advanced Age-related Macular Degeneration (AMD) using fundus photography
Description
Check the Progression to advanced Age-related Macular Degeneration (AMD) using fundus photography in the baseline, 6, 16 weeks
Time Frame
baseline, 6, 16 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
50 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
50 years or older
Has a confirmed diagnosis of early to moderate AMD
According to Staging of age-related macular degeneration of Beckman Initiative for Macular Research Classification Committee
early AMD: Medium drusen(>63 μm; ≤125 μm) and No AMD pigmentary abnormalities
moderate AMD: Large drusen(>125 μm) and/or Any AMD pigmentary abnormalities
Best Corrected Visual Acuity [BCVA] of 20/200 or better measured by Early Treatment Diabetic Retinopathy Study(ETDRS) Charts
A person who voluntarily agreed to participate in this clinical trial
Exclusion Criteria:
Subject who is observed to have a atrophy of 175 micrometers or more in diameter invading the fovea on fundus examination or fundus autofluorescent with more than one eye
Subject who is observed to have exudative macular degeneration on fundus examination or optical coherence tomography(OCT) with more than one eye
Has a history of intravitreal injection, laser treatment, etc.
Has eye pathology other than early age-related macular degeneration that may affect the outcome of clinical trials.
Has a history of vitrectomy due to macular disease or cataract surgery within 1 month
Has a disease that is judged to be difficult to interpret an ophthalmic imaging examination due to ocular media opacity
Has a history of uncontrollable systemic chronic disease(diabetes mellitus) or malignancy(cases that have not recurred for more than 5 years after complete recovery are excluded)
Autoimmune disease(Sjögren's syndrome, Rheumatoid arthritis, systemic lupus erythematosus, Graves' disease, etc.)
Has a severe hearing impairment
A person who is sensitive to orbit nerve stimulation and cannot be treated.
Has a history of substance and/or alcohol abuse
Has a confirmed diagnosis of psychiatric disease(depression, schizophrenia, bipolar disorder, dementia, etc)
Those who participated in other clinical trials within 30 days of the screening visit
Those who are judged to have "other reasons for prohibition of use" of our clinical trial medical device: heart-related problems. seizure. Patients transplanted metal or electronic device in head & neck including deep brain stimulation device. Patient suffering from unknown pain. Patients with implantable or wearable cardioverter defibrillator. Patients who are warned not to use out clinical trial device or is prohibited from using it. (Dental implants are accepted.)
In the case of subjects judged by the researcher that it would be difficult to participate in clinical trials
Among female subjects who are likely to be pregnant, those who disagree to contraception in a medically permitted manner during this clinical trial period.
Medically permitted contraception: condom, Oral contraception that lasted for at least 3 months, contraceptive injection, contraceptive implant, intrauterine device, etc.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Jinho Jung, Ph.D candidate
Phone
+821083113509
Email
jinho.jung@nueyne.com
First Name & Middle Initial & Last Name or Official Title & Degree
Nayoung Kang
Phone
+821073734097
Email
nayoung.kang@nueyne.com
Facility Information:
Facility Name
Korea University Ansan Hospital
City
Ansan
State/Province
Gyeonggi-do
ZIP/Postal Code
15355
Country
Korea, Republic of
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Cheol Min Yun, M.D., Ph.D.
First Name & Middle Initial & Last Name & Degree
Cheol Min Yun, M.D., Ph.D.
Facility Name
Asan Medical Center
City
Seoul
ZIP/Postal Code
05505
Country
Korea, Republic of
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Yoon Jeon Kim, M.D., Ph.D.
First Name & Middle Initial & Last Name & Degree
Yoon Jeon Kim, M.D., Ph.D.
Facility Name
Nune Eye Hospital
City
Seoul
ZIP/Postal Code
06192
Country
Korea, Republic of
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jong Min Kim, M.D., MS.
First Name & Middle Initial & Last Name & Degree
Jong Min Kim, M.D., MS.
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Study of Application of Transcutaneous Pulsed Electrical Stimulation Around Eye in Age-related Macular Degeneration
We'll reach out to this number within 24 hrs